undamentalytics Newsletter
Sign in

Kiniksa Pharmaceuticals International, plc (KNSA) stock

Add to watchlist

Add holding +

NASDAQ: KNSA Nasdaq Biotechnology Next results ~January 19, 2027

B+ Fundamentals grade

Kiniksa Pharmaceuticals International, plc is a US-listed company in the biotechnology industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

~$46

Cash-flow model

Base case. Range ~$37–$59 across our lower- and higher-growth cases (8%–18% a year).

Price vs value

Overvalued

The price is above our entire value range; our base value is 49% below it.

Price used: $90.80, November 2, 2026

Kiniksa Pharmaceuticals International, plc valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders0 buying, 8 selling0 purchases and 37 sales by directors and officers, last 12 monthsInsider trades
  • Funds153 adding, 106 cuttingOf 49 active managers that changed their stake, 21 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Kiniksa Pharmaceuticals International files

Where Kiniksa Pharmaceuticals International stands after its latest 10-Q

Revenue for the twelve months to September 2026 was $946m, up 58.2% on a year earlier, slower than the 58.9% growth a quarter earlier. Free-cash-flow margin rose to 20.8% from 17.0% a year earlier. Operating margin widened to 13.8% from 6.4%. The diluted share count is up 8.5% on a year earlier, which dilutes existing holders. Against its peers on growth, profitability, cash generation and balance sheet, it grades B+. It passes 2 of our 2 financial-health checks. Our cash-flow model value is $42.41 a share.

Source: 10-Q filed October 27, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~January 19, 2027 (estimated)

Kiniksa Pharmaceuticals International, plc's trailing-twelve-month revenue grew 58.2% year on year, with a free-cash-flow margin of 20.8%. Where it stands out: days sales outstanding of 12 days ranks 7 of 100 biotechnology companies we cover.

Our discounted-cash-flow model values the business at ~$46 per share in the base case (~$37–$59 across growth scenarios) — model values under stated assumptions, not a price target.

Current signal Free cash flow diverging from earnings: TTM free cash flow grew 93.8% while net income grew 205.1%: a 111pp divergence.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Fast growth. Revenue grew 58.2% over the last 12 months, against a median of 12.6% for biotechnology companies we cover.
  • Margins widening. Operating margin is up 7.4 points on a year ago.
  • Strong cash generation. 20.8% of revenue turned into free cash flow, against a median of -145.4% for biotechnology companies we cover.
  • Estimates rising. Analysts' consensus for next year's earnings per share has risen 33.2% over 90 days.

Things to watch

  • Priced above our value. The share price of $90.80 is 49% above our value per share of $46.
  • Share dilution. Diluted shares rose 8.5% in a year.
  • High earnings multiple. The shares trade at 69 times the last 12 months' earnings, so expectations are demanding.
  • Volatile shares. Over the past year the shares showed annualised volatility of 55% and a beta of 0.4 against the S&P 500.
  • Insiders selling. 8 insiders sold $45M of stock over the past 365 days and none bought (99% under pre-set trading plans).

Latest results: FY2026 Q3

Filed October 27, 2026
Earnings per share
$0.56 against an average estimate of $0.31: beat by 79.2%
Revenue
$286m, up 58.1% on a year earlier
Share reaction
+30.4% in the first session after the results on October 27, 2026, against +0.9% for the S&P 500
Next report
October 27, 2026; average EPS estimate $0.39

Kiniksa Pharmaceuticals International's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-1.6%
  • 1 week+24.4%
  • 1 month+19.8%
  • This year+120.1%
  • 1 year+145.3%
  • 5 years+502.9%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$946M
Operating margin
13.8%
Net margin
11.6%
EPS (TTM, diluted)
$1.32

Growth

Revenue growth
+58.2%
Change in growth rate
−0.7 pts
Share count change
+8.5%

Cash

Free cash flow (TTM)
$197M
FCF margin
20.8%
Stock pay % of revenue
4.8%

Earnings

Last results
October 27, 2026
Next results (est.)
January 19, 2027

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Results
  2. Leadership
  3. Results

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Kiniksa Pharmaceuticals International, plc valuation models and calculator

What the price is pricing in

The share price implies about 29.4% a year of cash-flow growth for five years.That is slower than the 89.7% a year revenue growth Kiniksa Pharmaceuticals International has delivered.

  • Priced in29.4%
  • Last 12 months58.2%
  • 3 years a year56.1%
  • 5 years a year89.7%

Our cash-flow model with every input fixed except growth over the next five years, solved for the growth at which the model value equals the share price ($92.36, Nov 3, 2026). Cash-flow growth then fades to 2.5% a year; discount rate 8.5%. Delivered figures are revenue growth from SEC filings. This is a model exercise, not investment advice or a forecast of the share price. All companies

Fundamentalytics rating

model v1.6 · 2026-11-03
Sell12-month view
12-month price target
~$46
Price used
$92.36close November 3, 2026
Implied change
▼ 50%
Uncertainty
Low

How we got here: a discounted-cash-flow model of Kiniksa Pharmaceuticals International, plc's free cash flow after stock-based pay with after-tax interest added back ($98M, FY2026 Q3 TTM), growing 21.3% and 15.2% in the next two years (forecasts, guidance and its record), then back to 13% by year five, and fading to 2.5%, discounted at 8.5%. Lower and higher growth cases span ~$37–~$59 ; that spread sets a 15% margin before we rate Buy or Sell.

Produced by Fundamentalytics' automated valuation model on November 3, 2026, using delayed market prices. Rating meanings, methodology and conflicts: recommendations disclosure and research disclaimer. General research, not personal advice — it does not consider your circumstances. Prices can fall as well as rise.

Our value per share comes from a discounted-cash-flow model of Kiniksa Pharmaceuticals International, plc's free cash flow after stock-based pay ( $98M, FY2026 Q3 TTM, with after-tax interest added back): growth for five years as below (the first two years from forecasts, guidance and the company's record), fading to 2.5%, discounted at 8.5%, then cash added and debt and other claims subtracted. These are model values under stated assumptions, not price targets or recommendations.

Valuation models

We value Kiniksa Pharmaceuticals International, plc as an operating company, with every model that fits that kind of business. Cost of equity 9%: the 10-year Treasury yield (4.9%) plus a beta of 0.91 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Cash-flow model (DCF) Free cash flow to the firm (after stock pay, with after-tax interest added back), grown then faded to 2.5%, discounted at 8.5% as the firm rate, less debt and other claims. ~$46 ~$37–$59 Primary model, counts double
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. ~$12 ~$9.5–$27 Left out: out of range vs price (0.13x)
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. ~$14 ~$9.9–$19 Left out: out of range vs price (0.15x)
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. ~$15 ~$13–$18 Left out: out of range vs price (0.16x)
Combined value Weighted average of the models that apply: the primary model (cash-flow model (dcf)) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. ~$46 ~$37–$59 1 model

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Kiniksa Pharmaceuticals International, plc with Biotechnology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

What moves the value

  • Revenue growth 5 points lower ▼ −22%
  • Revenue growth 5 points higher ▲ +29%
  • Free-cash-flow margin 1 point lower ▼ −5%
  • Last year's free-cash-flow margin change, if it persists ▲ +21%
  • Discount rate 1 point higher ▼ −15%
Value per share under different assumptions
Discount rate ↓ / growth → −5% growth0% growth5% growth10% growth15% growth20% growth
7% $23$29$37$48$61$79
8.5% $19$24$29$37$47$59
10% $17$20$25$31$38$47

Valuation multiples over time Market data may be delayed

At fiscal year end 20212022202320242025Now
Share price$11.77$14.98$17.54$19.78$41.25$90.80
Market value$807m$1.1bn$1.3bn$1.4bn$3.3bn$7.5bn
+ Net debt (− = net cash)−$122m−$123m−$108m−$184m−$166m−$82m
Enterprise value$685m$932m$1.2bn$1.2bn$3.1bn$7.5bn
Multiples
Price / sales 20.9x4.8x4.7x3.3x4.8x8.0x
Price / earnings —5.8x89.6x—55.2x68.9x
Price / free cash flow —185.0x95.8x55.6x23.9x38.3x
EV / EBITDA —76.6x——39.3x56.7x

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

16 /100

Weak moat

How hard Kiniksa Pharmaceuticals International's competitive advantage looks for rivals to wear away, judged from 9 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Net income has been a median -1.6% of total assets over 9 years.

  • Durability 10 / 20

    Operating margin has been a median -6.8%; its worst year was -18.3%.

  • Discipline 3 / 20

    The diluted share count rose 21.6% over five years; stock-based pay has been a median 7.9% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (21 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current $1.91 +155% $1.0bn +55%
Next $2.15 +13% $1.3bn +24%

Next year's EPS estimate has moved +33.2% in 90 days, across 2 analysts.

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is +65.0% on 90 days ago. In the last 30 days, 1 analyst raised Kiniksa Pharmaceuticals International, plc's forecast and 2 cut it.

Consensus EPS forecast Kiniksa Pharmaceuticals International, plc, last 90 days
$1.00 $1.50 $2.00 $2.50 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: $1.16 Current fiscal year, 60 days ago: $1.16 Current fiscal year, 30 days ago: $1.16 Current fiscal year, 7 days ago: $1.16 Current fiscal year, Now: $1.91 $1.91 Next fiscal year, 90 days ago: $1.62 Next fiscal year, 60 days ago: $1.62 Next fiscal year, 30 days ago: $1.62 Next fiscal year, 7 days ago: $1.62 Next fiscal year, Now: $2.15 $2.15

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago $1.16$1.62
60 days ago $1.16$1.62
30 days ago $1.16$1.62
7 days ago $1.16$1.62
Now $1.91$2.15

Earnings against estimates

Quarter toEstimateActualSurprise
Sept 2026 $0.31 $0.56 +79.2%
Jun 2026 $0.28 $0.30 +5.3%
Mar 2026 $0.16 $0.27 +68.8%
Dec 2025 $0.40 $0.17 −57.3%

Adjusted EPS as companies report it, against the average analyst estimate.

How our valuation uses these forecasts

Our cash-flow model grows Kiniksa Pharmaceuticals International, plc's revenue by +21.3% next year and +15.2% the year after, then fades back toward its own record by year five. Next year's rate weighs analysts' consensus (+31.3%, weight 45%) and the company's own record (+13.0%, weight 55%) . How the weights are set.

Analyst recommendations

7 analysts, Oct 2026
Buy7100%
Hold00%
Sell00%

Monthly trend

  1. Oct 2026167
  2. Sep 2026178
  3. Aug 2026178
  4. Jul 2026178

Counts of recommendations published by analysts covering Kiniksa Pharmaceuticals International, plc, by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
9.3%
of tradable shares
Days to cover
6.53
at average volume
Short interest, 1 month
−3%
to October 15, 2026
Held by institutions
—
of shares
Held by insiders
3.5%
of shares
Employees
366
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

What moved the share price

Last 12 months +145.3%

$37.01 on October 31, 2025 to $90.80

ThenNowEffect
Revenue (last 12 months) $529m $841m +58.9%
Net margin 0.9% 9.6% +960.0%
P/E multiple n/m 92.2x −84.0%
Share count 75m 82m −9.0%

Biggest factor: net margin.

Last 3 years +460.5%

$16.20 on November 3, 2023 to $90.80

ThenNowEffect
Revenue (last 12 months) $281m $841m +199.4%
Net margin 82.3% 9.6% −88.4%
P/E multiple 5.0x 92.2x +1749.7%
Share count 71m 82m −13.1%

Biggest factor: p/e multiple.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
KNSA−33%+27%+17%+13%+109%+120%
Industry peers (median)−36%−57%−18%−29%−5%−27%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
KNSA50%42%50%42%75%73%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
KNSA−57%−39%−34%−29%−22%−21%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since May 25, 2018: 83% from September 20, 2018 to October 18, 2019. Getting back needed a 490% gain, reached on August 1, 2025, 2114 days after the low.

Price behaviour

52-week range
$37.47 – $97.56
From 52-week high
−6.9%
vs 50-day average
+14.4%
vs 200-day average
+50.2%
Volatility (1 year)
55%
Beta vs S&P 500
0.37

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
7 up, 5 down
typical move ±15.5%
After a week
6 up, 5 down
typical move ±15.4%
After a month
8 up, 3 down
typical move ±15.2%
Results releasedNext dayS&P 500 next day5 days21 days
October 27, 2026 +30.4% +0.9% — —
July 28, 2026 +27.4% −1.3% +19.6% +23.8%
April 28, 2026 +21.5% −0.5% +30.1% +16.6%
February 24, 2026 −9.8% +1.6% −4.3% −3.3%
January 12, 2026 −9.5% 0.0% −3.8% +5.4%
October 28, 2025 −7.9% +0.3% −5.1% +4.8%
July 29, 2025 +11.2% −0.4% +22.3% +24.6%
April 29, 2025 +25.6% +0.7% +25.5% +26.6%
February 25, 2025 +0.3% −0.4% +8.7% +15.9%
January 13, 2025 −8.0% +0.3% −6.1% −3.3%
October 29, 2024 −16.6% −0.1% −20.2% −19.1%
July 23, 2024 +17.8% −2.4% +23.8% +23.6%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Options strategies

All options ideas

How Kiniksa Pharmaceuticals International, plc’s listed options are priced, and three ways to use them that follow from our valuation. Quotes are delayed, read November 2, 2026. Check the live chain at your broker before trading.

Cash-secured put

Not offered: rated Sell.

We suggest selling a put only on well-rated companies, at a strike where the price you would pay if assigned (strike less premium) is at or below our fair value.

Covered call

Not offered: no liquid call at or above our price target — the model says the upside is worth more than any listed strike.

For holders: sell a call at a strike at or above our fair value, so the shares are only sold at a price the model calls full value.

Collar

Not offered: no liquid put and call pair for the same expiry.

For holders of a stock trading at or above our fair value: buy a put for a floor and sell a call to pay for it.

General research, not personal advice. Options can lose you more than you expect and are not suitable for everyone: put sellers can be made to buy shares that keep falling, call sellers give up gains above the strike, and results or news can move prices sharply. Chances shown are approximations from each option’s delta. Spreads, fees and early assignment are not modelled.

Kiniksa Pharmaceuticals International, plc in five measures

Fundamentals grade B+
Growth Profitability Cash Balance sheet Value

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Kiniksa Pharmaceuticals International, plc
$0 $500M $1B FY23 Q4 FY24 Q3 FY25 Q2 FY26 Q3 Revenue (TTM), FY23 Q4: $270.3M Revenue (TTM), FY24 Q1: $301.8M Revenue (TTM), FY24 Q2: $338.9M Revenue (TTM), FY24 Q3: $384.1M Revenue (TTM), FY24 Q4: $423.2M Revenue (TTM), FY25 Q1: $481.2M Revenue (TTM), FY25 Q2: $529.3M Revenue (TTM), FY25 Q3: $598M Revenue (TTM), FY25 Q4: $677.6M Revenue (TTM), FY26 Q1: $754M Revenue (TTM), FY26 Q2: $840.8M Revenue (TTM), FY26 Q3: $946M $946M

Source: SEC EDGAR filings. Retrieved October 31, 2026.

View chart data
Period Revenue (TTM)
FY23 Q4 $270.3M
FY24 Q1 $301.8M
FY24 Q2 $338.9M
FY24 Q3 $384.1M
FY24 Q4 $423.2M
FY25 Q1 $481.2M
FY25 Q2 $529.3M
FY25 Q3 $598M
FY25 Q4 $677.6M
FY26 Q1 $754M
FY26 Q2 $840.8M
FY26 Q3 $946M
Revenue growth, TTM YoY Kiniksa Pharmaceuticals International, plc
0% 20% 40% 60% 80% FY23 Q4 FY24 Q3 FY25 Q2 FY26 Q3 Revenue growth, TTM YoY, FY23 Q4: 22.7% Revenue growth, TTM YoY, FY24 Q1: 27.7% Revenue growth, TTM YoY, FY24 Q2: 20.7% Revenue growth, TTM YoY, FY24 Q3: 54.4% Revenue growth, TTM YoY, FY24 Q4: 56.6% Revenue growth, TTM YoY, FY25 Q1: 59.4% Revenue growth, TTM YoY, FY25 Q2: 56.2% Revenue growth, TTM YoY, FY25 Q3: 55.7% Revenue growth, TTM YoY, FY25 Q4: 60.1% Revenue growth, TTM YoY, FY26 Q1: 56.7% Revenue growth, TTM YoY, FY26 Q2: 58.9% Revenue growth, TTM YoY, FY26 Q3: 58.2% 58.2%

Source: SEC EDGAR filings. Retrieved October 31, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q4 22.7%
FY24 Q1 27.7%
FY24 Q2 20.7%
FY24 Q3 54.4%
FY24 Q4 56.6%
FY25 Q1 59.4%
FY25 Q2 56.2%
FY25 Q3 55.7%
FY25 Q4 60.1%
FY26 Q1 56.7%
FY26 Q2 58.9%
FY26 Q3 58.2%
Operating margin (TTM) Kiniksa Pharmaceuticals International, plc
-20% -10% 0% 10% 20% FY23 Q4 FY24 Q3 FY25 Q2 FY26 Q3 Operating margin (TTM), FY23 Q4: -9.3% Operating margin (TTM), FY24 Q1: -10.1% Operating margin (TTM), FY24 Q2: -8.1% Operating margin (TTM), FY24 Q3: -6.8% Operating margin (TTM), FY24 Q4: -10.8% Operating margin (TTM), FY25 Q1: -3.3% Operating margin (TTM), FY25 Q2: 0.8% Operating margin (TTM), FY25 Q3: 6.4% Operating margin (TTM), FY25 Q4: 11.4% Operating margin (TTM), FY26 Q1: 12.4% Operating margin (TTM), FY26 Q2: 11.9% Operating margin (TTM), FY26 Q3: 13.8% 13.8%

Source: SEC EDGAR filings. Retrieved October 31, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q4 -9.3%
FY24 Q1 -10.1%
FY24 Q2 -8.1%
FY24 Q3 -6.8%
FY24 Q4 -10.8%
FY25 Q1 -3.3%
FY25 Q2 0.8%
FY25 Q3 6.4%
FY25 Q4 11.4%
FY26 Q1 12.4%
FY26 Q2 11.9%
FY26 Q3 13.8%
FCF margin (TTM) Kiniksa Pharmaceuticals International, plc
0% 10% 20% 30% FY23 Q4 FY24 Q3 FY25 Q2 FY26 Q3 FCF margin (TTM), FY23 Q4: 4.9% FCF margin (TTM), FY24 Q1: 7.1% FCF margin (TTM), FY24 Q2: 8.9% FCF margin (TTM), FY24 Q3: 2.9% FCF margin (TTM), FY24 Q4: 6.0% FCF margin (TTM), FY25 Q1: 9.1% FCF margin (TTM), FY25 Q2: 12.6% FCF margin (TTM), FY25 Q3: 17.0% FCF margin (TTM), FY25 Q4: 20.1% FCF margin (TTM), FY26 Q1: 21.8% FCF margin (TTM), FY26 Q2: 21.7% FCF margin (TTM), FY26 Q3: 20.8% 20.8%

Source: SEC EDGAR filings. Retrieved October 31, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q4 4.9%
FY24 Q1 7.1%
FY24 Q2 8.9%
FY24 Q3 2.9%
FY24 Q4 6.0%
FY25 Q1 9.1%
FY25 Q2 12.6%
FY25 Q3 17.0%
FY25 Q4 20.1%
FY26 Q1 21.8%
FY26 Q2 21.7%
FY26 Q3 20.8%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Where the money goes

FY2025, from the 10-K

Each dollar Kiniksa Pharmaceuticals International took in during FY2025, followed through to profit: what it cost to make, what went on research and running the business, and what was left after tax.

  1. Revenue $678M
  2. Other income $11.6M · 1.7%
  3. Cost of revenue $77.7M · 11.5%
  4. Gross profit $600M · 88.5%
  5. Research and development $96.9M · 14.3%
  6. Selling, general and admin $196M · 29.0%
  7. Other operating costs $230M · 33.9%
  8. Operating income $77.2M · 11.4%
  9. Income tax $29.9M · 4.4%
  10. Net income $59M · 8.7%

Shares of revenue. Source: Kiniksa Pharmaceuticals International's 10-K for FY2025, as filed with the SEC. "Other" lines are what the reported lines leave unexplained. Other income is income outside operations, such as investment gains.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Sept 2026
Income
Revenue 39 220 270 423 678 946
Gross profit 29 197 237 362 600 853
EBITDA −154 12 −23 −44 79 132
Operating income −157 10 −25 −46 77 130
Net income −158 183 14 −43 59 110
Diluted EPS −$2.30 $2.60 $0.20 −$0.60 $0.75 $1.32
Growth (year on year)
Revenue — +471.2% +22.7% +56.6% +60.1% +58.2%
EBITDA — — −287.7% — — +238.3%
Operating income — — −357.8% — — +241.9%
Net income — — −92.3% −406.7% — +205.1%
Diluted EPS — — −92.3% −400.0% — +181.1%
Margins
Gross margin 76.4% 89.6% 87.6% 85.6% 88.5% 90.2%
EBITDA margin −400.3% 5.5% −8.5% −10.4% 11.6% 13.9%
Operating margin −406.4% 4.4% −9.3% −10.8% 11.4% 13.8%
Net margin −409.7% 83.3% 5.2% −10.2% 8.7% 11.6%
Free-cash-flow margin −328.7% 2.6% 4.9% 6.0% 20.1% 20.8%
Cash flow
Cash from operations −126 6 13 26 138 199
Capital spending 0 0 0 0 2 2
Free cash flow −127 6 13 25 136 197
Stock-based pay 25 25 27 31 37 45
Free cash flow after stock pay −152 −19 −14 −5 99 152
Balance sheet
Cash 122 123 108 184 166 82
Total debt 0 0 0 0 0 0
Net debt (negative = net cash) −122 −123 −108 −184 −166 −82
Diluted shares 69m 70m 72m 71m 79m 83m

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

2 of 2 checks passed · September 30, 2026
What it owns · $983m
Short-term assets $750mLonger-term assets $233m
What it owes, and who funded it · $983m
Short-term liabilities $192mLonger-term liabilities $81mShareholders' equity $710m
  • Short-term assets cover short-term liabilities $750m of assets due within a year against $192m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $750m short-term assets against $81m of longer-dated liabilities.
  • More cash than debt Cash or debt not separately reported. Not assessable.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
  • Operating profit covers interest at least five times over Interest not separately reported. Not assessable.

From Kiniksa Pharmaceuticals International, plc's latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Diluted share count
+8.5%
year over year
R&D spending
14.4%
of revenue
Sales & admin spending
26.1%
of revenue
Days sales outstanding
12 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in biotechnology
Last 12 months unless stated KNSA BBIO BCRX IONS LEGN ASND Median
Revenue, last 12 months $946m $946m $941m $874m $1.0bn $814m $56m
Revenue growth, last 12 months 58.2% 167.3% 68.7% −7.4% 64.0% 106.9% 12.6%
Revenue growth, 3-year average 56.1% 364.6% 45.3% 11.5% — — 13.7%
Revenue growth, latest quarter 58.1% 192.6% 33.6% −40.7% — — 10.2%
Gross margin 90.2% 94.3% 97.8% 98.2% 61.4% 86.8% 82.9%
Operating margin 13.8% −38.5% −33.3% −68.0% −13.3% −18.9% −189.4%
Operating margin, 3-year average 4.4% −153.6% −13.1% −47.0% — <−999% −363.5%
Net margin 11.6% −59.8% −40.9% −64.7% −28.8% −31.7% −169.8%
Cash from operations / revenue 21.0% −39.0% 40.0% −56.8% −9.7% 7.5% −168.0%
Free-cash-flow margin 20.8% −39.1% 39.7% −64.2% −12.5% 7.5% −162.4%
Free-cash-flow margin, 3-year average 13.6% −137.4% 6.7% −46.3% — <−999% −310.0%
Stock pay / revenue 4.8% 16.1% 7.8% 18.7% — 16.1% 20.0%
Change in share count 8.5% 2.4% 11.4% −2.8% 0.8% 4.7% 8.2%

Median of all 184 companies we cover in biotechnology. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

184 biotechnology companies
Measure Company Peer median Rank
Revenue growth Growth 58.2% 12.6% 50 of 172
Change in growth rate Growth -0.7pp -0.1pp 90 of 172
Gross margin Profitability 90.2% 82.4% 21 of 75
Operating margin Profitability 13.8% -189.4% 25 of 175
Net margin Profitability 11.6% -157.3% 28 of 180
Free-cash-flow margin Cash generation 20.8% -145.4% 22 of 176
Stock pay as % of revenue Cash generation 4.8% 19.2% 32 of 179
Change in share count Balance sheet 8.5% 7.9% 84 of 156
Days sales outstanding Balance sheet 12 days 75 days 7 of 100

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Who owns it

Funds buying and selling
Reported value
$3B
Institutions reporting
264
Shares held vs prior quarter
▲ 3.4%
Positions opened / closed
68 / 26

Top buyers and sellers, Q2 2026: 153 institutions bought and 106 sold ; the biggest buyer was Blackrock, Inc (+2.3M shares) and the biggest seller Acadian Asset Management LLC (−657K). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
FMR LLC $446M 7.0M 14.9% ▲ 2.2%
Rubric Capital Management LP $256M 4.0M 8.6% ▲ 6.7%
Baker Bros. Advisors LP $181M 2.8M 6.1% ▲ 0.3%
Blackrock, Inc. $175M 2.7M 5.9% ▲ 462.9%
Tang Capital Management LLC $145M 2.3M 4.8% 0.0%
Vanguard Portfolio Management LLC $122M 1.9M 4.1% ▲ 8.2%
Vanguard Capital Management LLC $87M 1.4M 2.9% ▲ 2.1%
Morgan Stanley $64.7M 1.0M 2.2% ▲ 1.3%
Arrowstreet Capital, Limited Partnership $61.2M 958K 2.1% ▲ 7.3%
Spruce Street Capital LP $58.7M 918K 2.0% ▲ 20.6%
Dimensional Fund Advisors LP $55.9M 875K 1.9% ▲ 7.7%
Invesco Ltd. $49.4M 773K 1.7% ▲ 2694.4%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Kiniksa Pharmaceuticals International, plc's complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $44.8M 37 trades by 8 insiders · 99% under pre-set plans
Net ▼ $44.8M net selling
Insider Date Trade Shares Price Value
Megna Michael R CHIEF ACCOUNTING OFFICER September 3, 2026 Sell pre-set plan 4,600 $80.30 $369,380
Cole G Bradley Director July 29, 2026 Sell 3,673 $81.43 $299,092
Patel Sanj K CHAIRMAN & CEO May 1, 2026 Sell pre-set plan 48,565 $54.02 $2.6M
Paolini John F. CHIEF MEDICAL OFFICER May 1, 2026 Sell pre-set plan 21,097 $54.04 $1.1M
Paolini John F. CHIEF MEDICAL OFFICER May 1, 2026 Sell pre-set plan 37,327 $53.52 $2M
Patel Sanj K CHAIRMAN & CEO April 30, 2026 Sell pre-set plan 2,141 $54.01 $115,635
Patel Sanj K CHAIRMAN & CEO April 29, 2026 Sell pre-set plan 22,544 $54.01 $1.2M
Quart Barry D Director April 28, 2026 Sell pre-set plan 13,099 $50.10 $656,260
Patel Sanj K CHAIRMAN & CEO April 28, 2026 Sell pre-set plan 74,635 $50.43 $3.8M
Patel Sanj K CHAIRMAN & CEO April 28, 2026 Sell pre-set plan 113,673 $51.47 $5.9M
Patel Sanj K CHAIRMAN & CEO April 28, 2026 Sell pre-set plan 243,596 $52.02 $12.7M
Patel Sanj K CHAIRMAN & CEO April 28, 2026 Sell pre-set plan 51,750 $54.02 $2.8M

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around January 19, 2027 estimated from the company's past filing pattern, not announced

  • October 27, 2026
  • July 28, 2026
  • April 28, 2026
  • February 24, 2026
  • January 12, 2026
  • October 28, 2025

Recent SEC filings

Data status

When each part of this page on Kiniksa Pharmaceuticals International, plc was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Kiniksa Pharmaceuticals International, plc in brief

What does Kiniksa Pharmaceuticals International, plc do?
Kiniksa Pharmaceuticals International, plc is a US-listed company in the biotechnology industry. Its financial year ends in December.
What is Kiniksa Pharmaceuticals International, plc's stock ticker?
Kiniksa Pharmaceuticals International, plc trades under the ticker KNSA on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Kiniksa Pharmaceuticals International, plc's revenue, and how fast is it growing?
Over its most recent trailing twelve months, Kiniksa Pharmaceuticals International, plc reported revenue of $946M, 58.2% higher than a year earlier, according to its SEC filings.
What is Kiniksa Pharmaceuticals International, plc's free cash flow?
Kiniksa Pharmaceuticals International, plc's free-cash-flow margin is 20.8% of revenue over the trailing twelve months, ranking 22 of the 176 biotechnology companies we cover.
What is Kiniksa Pharmaceuticals International, plc's fair value (intrinsic value) per share?
Our discounted-cash-flow model of Kiniksa Pharmaceuticals International, plc's free cash flow after stock-based pay gives ~$46 per share in the base case, and ~$37–$59 across growth scenarios. These are model values under stated assumptions — not a price target or a recommendation.
Who are Kiniksa Pharmaceuticals International, plc's largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are FMR LLC, Rubric Capital Management LP and Baker Bros. Advisors LP. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Kiniksa Pharmaceuticals International, plc's market cap?
On November 2, 2026, Kiniksa Pharmaceuticals International, plc's market capitalisation was about $7.5B, with a price-to-earnings ratio of 68.9 and net debt of -$81.7M. Market figures come from third-party market data and may be delayed.
Who are Kiniksa Pharmaceuticals International, plc's competitors?
In our Biotechnology peer group, the companies closest to Kiniksa Pharmaceuticals International, plc are Bridgebio Pharma, Inc., Biocryst Pharmaceuticals Inc, Ionis Pharmaceuticals Inc, Legend Biotech Corp and Ascendis Pharma A/s. The side-by-side comparison below sets their revenue, margins and growth against Kiniksa Pharmaceuticals International, plc's.
Are insiders buying or selling Kiniksa Pharmaceuticals International, plc stock?
Over the last 12 months, Kiniksa Pharmaceuticals International, plc's directors and officers reported 0 open-market purchases and 37 sales on Form 4. The insider trading page charts every trade.
When is Kiniksa Pharmaceuticals International, plc's next earnings date?
Around January 19, 2027, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Kiniksa Pharmaceuticals International, plc announces its own schedule.